Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

Leukemia Research

Volumn 34, Issue 3, 2010, Pages 284-288

  Faderl, Stefan ^a   Wierda, William ^a   O'Brien, Susan ^a   Ferrajoli, Alessandra ^a   Lerner, Susan ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoimmunotherapy; Chronic lymphocytic leukemia (CLL); Mitoxantroe; Nucleoside analogs

Indexed keywords

BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD5 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; MITOXANTRONE; ONDANSETRON; PARACETAMOL; PROTEIN KINASE ZAP 70; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BRONCHITIS; CARDIOTOXICITY; CELLULITIS; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; INFECTION; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CELL SEPARATION; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOXANTRONE; PILOT PROJECTS; REMISSION INDUCTION; TREATMENT OUTCOME; VIDARABINE;

EID: 77649184591     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.008     Document Type: Article

References (13)

1. Dighiero G., Hamblin T.J. Chronic lymphocytic leukemia. Lancet 2008, 371:1017-1029.
2. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
3. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070-4078.
4. Hallek M., Fingerle-Rowson G., Fink A.-M., et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia. Blood 2008, 112:125. (abstract 325).
5. Robak T., Moiseev S.I., Dmoszynska A., et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphoyctic leukemia (CLL) compared with FC alone: final results from the International Randomized Phase III REACH Trial. Blood 2008, 112. LBA-1.
6. Boettcher S., Fischer K., Stilgenbauer S., et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trials. Blood 2008, 112:125. (abstract 326).
7. Bellosillo B., Villamor N., Colomer D., et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999, 94:2836-2843.
8. Bosch F., Ferrer A., López-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002, 119:976-984.
9. Bosch F., Ferrer A., Villamor N., et al. Fludrabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14:155-161.
10. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
11. Thall P.F., Simon R., Estey E.H. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 1996, 14:296-303.
12. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
13. Bosch F., Abrisqueta P., Villmor N., et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) is a highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. Blood 2008, 112:730. (abstract 2097).